Pancreaze Shortage: What Providers and Prescribers Need to Know in 2026

Pancreaze (pancrelipase, VIVUS LLC) is one of five FDA-approved pancreatic enzyme replacement therapy (PERT) products in the United States, indicated for the treatment of exocrine pancreatic insufficiency (EPI) in adult and pediatric patients. While Pancreaze is not currently listed on the FDA's official drug shortage database, the broader PERT market has experienced significant supply pressures since 2022, with downstream effects on Pancreaze availability at individual pharmacies.

This briefing is intended for prescribers managing EPI patients on Pancreaze — including gastroenterologists, pulmonologists, primary care physicians, and nurse practitioners. It covers the current supply landscape, clinical considerations for alternative prescribing, and tools to help your patients maintain uninterrupted enzyme replacement.

Current PERT Market Supply Status (2026)

The five-brand U.S. PERT market has operated under intermittent supply strain since late 2022, driven primarily by disruptions to Creon (AbbVie) — the dominant product accounting for the majority of PERT market volume. Creon supply disruptions have created ripple effects across the entire PERT category:

• Patient and provider switching to Pancreaze, Zenpep, and Pertzye increased demand on those supply chains.
• As of 2025–2026, Creon is not on the FDA shortage list, but regional and strength-specific availability gaps persist.
• No FDA-approved generic pancrelipase exists, and none is expected in the near term. The biological complexity of porcine-derived enzyme manufacturing makes generic development significantly more challenging than for small-molecule drugs.
• Global PERT market demand is growing at ~6% annually (valued at $3 billion in 2025), driven by increasing chronic pancreatitis prevalence, improved EPI diagnosis rates, and an aging population. Rising demand without proportionate capacity increases creates ongoing strain.

Pancreaze Regulatory and Supply Background

Pancreaze received FDA approval in April 2010 under NDA #022523, as part of the FDA's mandate requiring all pancreatic enzyme products to obtain formal NDAs by April 28, 2010. The brand was originally marketed by Ortho-McNeil-Janssen Pharmaceuticals and is now manufactured and commercialized by VIVUS LLC.

Pancreaze uses an enteric-coated microtablet formulation — each capsule contains microtablets approximately 2 mm in diameter that resist dissolution at low pH and release enzymes at pH ≥ 5.5 in the small intestine. The active ingredient is dosed by lipase units, and all six strengths (2,600; 4,200; 10,500; 16,800; 21,000; and 37,000 lipase units) use a phthalate-free formulation.

As of January 2026, VIVUS reports Pancreaze is covered on 81% of commercial insurance plans, with prior authorization required by some plans.

Clinical Considerations When Pancreaze Is Unavailable

If a patient cannot obtain their prescribed Pancreaze strength, the following clinical framework can guide decision-making:

Step 1: Confirm the Unavailability

Before assuming Pancreaze is unavailable, verify that the patient or your office has checked multiple pharmacies. medfinder for providers is a service that can contact multiple pharmacies on behalf of a patient to confirm which ones have a specific medication and strength in stock. Referring patients to this service can save significant time for both the patient and your staff.

Step 2: Consider Equivalent Dosing with Available PERT Alternatives

PERT products are NOT interchangeable — each requires a separate prescription. However, clinical switching is appropriate and recommended when a prescribed product is unavailable. Dosing conversion should be based on total daily and per-meal lipase units. The following summary provides a starting framework:

• Creon (AbbVie): Available in 3,000; 6,000; 12,000; 24,000; 36,000; and 60,000 lipase units. Most commonly prescribed PERT in the U.S., though subject to its own supply pressures.
• Zenpep (Aimmune): Available in 3,000; 5,000; 10,000; 15,000; 20,000; 25,000; and 40,000 lipase units. Wide range of strengths offers flexibility in dose matching.
• Pertzye (Digestive Care): Available in 8,000; 16,000; and 24,000 lipase units. Bicarbonate-buffered formulation may benefit patients with altered gastric physiology. Appropriate for CF and other EPI etiologies.
• Viokace (Aimmune): Non-enteric coated. Indicated for chronic pancreatitis and pancreatectomy (not CF). Requires concurrent PPI therapy. Generally not appropriate as a direct Pancreaze substitute for CF patients.

Adhere to maximum dosing limits regardless of product: do not exceed 2,500 lipase units/kg/meal or 10,000 lipase units/kg/day. Monitor closely for signs of inadequate replacement (steatorrhea, weight loss, abdominal symptoms) and for excessive dosing (fibrosing colonopathy risk).

Documenting Alternative Prescribing

When prescribing an alternative PERT due to Pancreaze unavailability, document the following in the patient's chart:

• Patient's current Pancreaze strength and total daily lipase dose
• Alternative product and strength prescribed
• Rationale for the switch (pharmacy unavailability)
• Plan to return to Pancreaze when available, if preferred by patient or indicated clinically
• Monitoring plan for symptom assessment and dose titration

Patient Communication Guidance

Proactively communicating with EPI patients about supply chain realities can reduce emergency calls and last-minute prescription change requests. Consider advising patients to:

• Request refills 5–7 days before running out.
• Identify a backup pharmacy that reliably stocks their Pancreaze strength.
• Know the name of the Vivus Patient Assistance Program (1-855-751-5540) if cost is a barrier.
• Use medfinder when they can't locate their medication at their usual pharmacy.

Outlook for 2026 and Beyond

The structural constraints affecting the PERT market — porcine sourcing complexity, no generic competition, rising demand — are unlikely to resolve quickly. Providers who build proactive access planning into their EPI patient management will be best positioned to ensure continuity of care. See also our companion resource: How to Help Your Patients Find Pancreaze in Stock: A Provider's Guide.